CD47 and non-Hodgkin lymphoma: In 2018, Advani et al. published the results of a phase 1b study involving 22 patients with relapsed or refractory NHL that were treated with Hu5F9-G4 (hereafter Magrolimab), which is a mAb against CD47, and rituximab (mAb against CD-20).